Arthritis Clinical Trials in Birmingham
View 29 new treatments for Arthritis in Birmingham, AL. Every day, Power helps hundreds of Arthritis patients connect with leading medical research.Filter Results
Condition
All
How old are you?
Trial Phase
All
Trial Status
All
COVID-19 VaccinE Response in Rheumatology Patients
Research Clinic, Hoover + 3 more
This trial tests an extra dose of the COVID-19 vaccine in patients with autoimmune diseases. It aims to see if pausing their medications temporarily can make the vaccine more effective. The goal is to improve their immune response to COVID-19.Show More
Recruiting
No Placebo Trial
Phase 4
Est. 6 - 12 Weeks
Jeffrey R Curtis, MD MS MPH
Principal Investigator
COVID-19 Vaccines for Rheumatic Diseases
Research Clinic, Northport + 1 more
Based on the experience with influenza, pneumococcal, and shingles vaccinations in rheumatic disease populations, it is clear that some disease modifying anti-rheumatic drugs and the immunomodulatory therapies used to treat immune-mediated inflammatory diseases have the capacity to blunt immune responses to COVID-19 vaccines. Several studies have suggested that patients with autoimmune conditions may be at increased risk of poor COVID-19 outcomes. There is an urgent need to better clarify the immunogenicity and safety of COVID-19 vaccines in people living with rheumatic disease who use immunomodulatory therapies. Boosters at annual or other frequency are available, and there is a need to understand whether these vaccines can be given concurrently with other routine vaccines.Show More
Waitlist
No Placebo Trial
Phase 4
Est. 6 - 12 Weeks
Unregistered Study Lead
Research Team
TG-C for Knee Osteoarthritis
Kolon TissueGene Clinic, Birmingham + 1 more
This trial tests TG-C, an injection into the knee, for people with moderate to severe knee osteoarthritis. It aims to see if TG-C can reduce pain and improve knee function by potentially altering the disease. The study will monitor patients for safety and effectiveness over time. TG-C has been previously studied for its potential to improve knee joint function and reduce pain in osteoarthritis patients.Show More
Waitlist
Phase 3
Est. 6 - 12 Weeks
David W Romness, MD
Principal Investigator
Non-Surgical Interventions for Knee Osteoarthritis
Research Clinic, Birmingham + 1 more
There is an urgent public health need to reduce reliance on opioids for effective long-term pain management, particularly in knee osteoarthritis (KOA). This effectiveness trial will compare commonly recommended treatments to reduce pain and functional limitations in KOA.These results will lead to improved patient selection for treatment and inform evidence based guidelines by offering well-tested, effective, non-surgical alternatives.Show More
Recruiting
No Placebo Trial
Phase 3
Est. 6 - 12 Weeks
Steven Cohen, MD
Principal Investigator
Amniotic Suspension Allograft for Knee Osteoarthritis
Organogenesis Clinic, Birmingham + 2 more
This trial is testing if injecting ASA into the knee can help people with knee osteoarthritis feel better. The study will check pain levels, knee function, and safety over several months. ASA (Amniotic Suspension Allograft) has been shown to be an effective treatment for knee osteoarthritis in previous studies.Show More
Recruiting
Phase 3
Est. 6 - 12 Weeks
Unregistered Study Lead
Research Team
RTX-GRT7039 Injection for Osteoarthritis
GrĂ¼nenthal Clinic, Birmingham + 1 more
This trial tests a special injection called RTX-GRT7039 to help reduce knee pain in people with osteoarthritis who still have pain despite usual treatments. The injection works by blocking pain signals from the knee.Show More
Waitlist
Phase 3
Est. 5 - 8 Weeks
Unregistered Study Lead
Research Team
Non-TNFi Biologics vs Targeted Synthetic DMARDs for Rheumatoid Arthritis
Research Clinic, Birmingham + 2 more
This trial is testing advanced medications for RA patients who haven't responded to standard treatments. It compares biologic drugs that target immune proteins and synthetic drugs that block harmful molecules in immune cells. The goal is to see which treatment improves patients' quality of life and daily functioning better. Biologic therapies have notably improved the treatment of RA, making disease remission a realistic goal.Show More
Recruiting
No Placebo Trial
Phase 3
Est. 3 - 6 Weeks
Jasvinder Singh, MD
Principal Investigator
Health Coaching + Incentives for Knee Osteoarthritis
Research Clinic, Birmingham + 1 more
The aims are to determine whether 1) an incentive based on behaviorally-enhanced gamification and social incentives and 2) health coaching can promote adherence to exercise and physical activity after physical therapy for osteoarthritis of the knee (KOA). The research design is a randomized clinical trial with factorial design This randomized clinical trial of 254 patients using a factorial design will leverage a clinical trial platform developed through the University of Pennsylvania that allows for the remotely capture important patient-reported outcomes and other interaction through a participant's smart phone. The investigators will randomize participants to receive social incentives with gamification to promote adherence to prescribed exercises as well as maintenance of greater levels of physical activity and compare to controls that receive a Fitbit but no additional incentive. Participants may also be randomized to receive a health coach. The investigators will utilize mobile applications for smart phones and wearable activity trackers through the Way-to-Health platform and assess, in real time, the impact of the interventions on patient-reported function and pain (as measured by the Knee Osteoarthritis Outcome Score) as well as physical activity. Participants will be followed for 2 years, with a total of 5 in-person visits. Knee osteoarthritis (KOA) is one of the most prevalent and disabling conditions among Veterans and accounts for high morbidity and high costs for the VA. Importantly, while physical therapy is valuable for patients with KOA, lack of adherence to home exercises and low overall physical activity limit the durability of response. The current proposal aims to address two important knowledge gaps in the management of KOA in order to improve pain and function.Show More
Waitlist
No Placebo Trial
Phase 3
Est. 6 - 12 Weeks
Joshua F. Baker, MD MSCE
Principal Investigator
Guselkumab for Psoriatic Arthritis
Janssen Clinic, Birmingham + 1 more
The purpose of this study is to evaluate the efficacy of guselkumab treatment in participants with active psoriatic arthritis (PsA) by assessing the reduction in signs and symptoms of PsA.Show More
Recruiting
Phase 3
Est. 3 - 6 Weeks
Janssen Research & Development, LLC Clinical Trial
Study Director
Ustekinumab/Guselkumab for Juvenile Psoriatic Arthritis
Janssen Clinic, Birmingham + 1 more
The purpose of this study is to evaluate the pharmacokinetics (PK), efficacy, safety and immunogenicity of ustekinumab and guselkumab in active juvenile psoriatic arthritis (jPsA).Show More
Recruiting
No Placebo Trial
Phase 3
Est. 4 - 6 Weeks
Janssen Research & Development, LLC Clinical Trial
Study Director
Page 1 of 4
Frequently Asked Questions
Explore related conditions